Background Aflatoxins are fungal secondary metabolites negatively affecting ruminant performance; however, little information is available on their impact on rumen fermentation. Aims This study aimed at determining the effects of different concentrations of aflatoxin B1 (AFB1) from Aspergillus flavus on in vitro gas production and ruminal fermentation parameters using two experiments (Exp.). Methods In Exp. 1, two concentration ranges (0, 0.5, 1, and 1.5 µg/ml of rumen inoculum as low and 0, 5, and 10 µg/ml as high concentration ranges) were used to evaluate AFB1 effect on gas production kinetics using 96-h incubations. In Exp. 2, only the high concentration range was used to investigate AFB1 effects on ruminal fermentation parameters using 24-h incubations. Results In the low concentration range, the half-time of asymptotic gas production (T1/2) increased and the fractional rate of gas production (µ) decreased linearly with AFB1 dosage (P less then 0.05). However, in the high concentration range, the asymptotic gas production (A) and T1/2 decreased; and the lag time (L) and "µ" increased linearly (P less then 0.001) by increasing the concentrations of AFB1. In Exp. 2, dry matter (DM) and organic matter (OM) disappearance, microbial biomass (MB) and total volatile fatty acids (TVFA) concentrations were depressed, but pH and ammonia-N concentration increased (P less then 0.01) by increasing the concentrations of AFB1. The pattern of rumen volatile fatty acids (VFAs) was also modified by AFB1, as the propionate proportion increased at the expense of acetate. Conclusion Aflatoxin B1 had an adverse effect on in vitro ruminal fermentation parameters in high concentration ranges (5 and 10 µg/ml).Background Diarrheagenic Escherichia coli (DEC) is regarded as a great public health concern all around the world causing diarrhoea which can be transmitted through food chain. Aims This study aimed to determine the contamination level and exact distribution rate of DEC in food products consumed by human. Methods Seven hundred and twenty samples of food from animal origin and fishes were analysed by conventional and molecular method for the presence of E. coli and two multiplex polymerase chain reaction (mPCR) for detection of DEC. Results Two hundred and eighty-three E. coli isolates were detected. The classification of DEC by two multiplex PCR assay yielded 84 DEC pathotypes. Enterotoxigenic E. coli (ETEC) was detected at high rates (75%) followed by shiga-toxigenic E. coli (STEC) and enterohemorrhagic E. coli (EHEC) (each of 9.5%), enteroaggregative E. coli (EAEC) (3.5%) and atypical enteropathogenic E. coli (aEPEC) (about 2.3%). The highest number of DEC (n=26; 21.6%) was observed from beef carcasses in abattoir while the lowest number (n=7; 5.8%) was noticed from burger samples (P0.05). Conclusion High DEC contamination rate that was observed is attributed to the poor hygienic practices during food processing. Therefore, a superior hygienic application is required.Listeria monocytogenes, as a foodborne pathogenic bacterium, is considered as major causative agent responsible for serious diseases in both humans and animals. Milk and dairy products are among the main sources of energy supply in the human, therefore contamination of these products with Listeria spp., especially L. monocytogenes, could lead to life threatening infections in a large population of people. Rapid and accurate detection of L. monocytogenes in milk and dairy products, vegetables, meat, poultry, and seafood products is needed to prevent its dissemination through the food chain. Upon contamination of food materials with this pathogen, increase in its antibiotic resistance rate can occur after exposure to preservatives, antibiotics, and stress conditions, which has now become another major public health concern emphasizing the need for special attention on its control along the food chain and management of the disease in the patients. This review provides an overview of researches with respect to the prevalence of Listeria spp., especially L. monocytogenes, in milk and dairy products, methods of their detection and typing, and current status of resistance rates to the antibiotics used for treatment of listeriosis.[This corrects the article DOI 10.1186/s13223-019-0391-9.]. © The Author(s) 2020.Background To evaluate the effects of fluticasone furoate on the hypothalamic-pituitary-adrenocortical axis, and the safety and tolerability of fluticasone furoate treatment in children with asthma. Methods This was a randomized, double-blind, placebo-controlled, multicenter, stratified, parallel-group, non-inferiority study of fluticasone furoate 50 µg inhalation powder administered once daily. The study enrolled children (aged 5-11 years inclusive) with a documented diagnosis of asthma for ≥ 6 months and a Childhood Asthma Control Test score of > 19. After a 7-14-day run-in period, eligible subjects were stratified by age and randomized to fluticasone furoate 50 µg once daily or placebo once daily via ELLIPTA for 6 weeks. https://www.selleckchem.com/products/msdc-0160.html The primary endpoint was the change from baseline (expressed as a ratio) in 0-24-h weighted mean serum cortisol at the end of the treatment period. Results Fifty-six randomized subjects received fluticasone furoate 50 µg once daily and 55 received placebo. The primary analysis was performed in the serum cortisol population (n = 104) and demonstrated that fluticasone furoate 50 µg once daily was non-inferior to placebo (ratio = 0.93; 95% confidence interval 0.8096, 1.0620), as the lower limit of the 95% confidence interval for the geometric mean treatment ratio of fluticasone furoate 50 µg once daily versus placebo was greater than 0.80. Findings from the intent-to-treat population (n = 111) were similar. Conclusions Six weeks of treatment with inhaled fluticasone furoate 50 µg once daily had no clinically relevant effect on the hypothalamic-pituitary-adrenocortical axis function of children, as measured by 24-h serum cortisol profiles. The primary analysis showed that fluticasone furoate 50 µg once daily was non-inferior to placebo. Fluticasone furoate 50 µg once daily was well tolerated and no new safety concerns emerged during the study. Trial registration This study is registered in ClinicalTrials.gov (NCT02483975). Date of submission 25 June 2015. © The Author(s) 2020.

Copyright © 2020 Hoogeveen and Boonstra.The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis. Indoleamine-2,3-dioxygenase (IDO) activity exerts a protective function, limiting the severity of experimental arthritis, whereas deletion or inhibition exacerbates the symptoms. Other chronic disorder with an inflammatory component, such as atherosclerosis, are also suppressed by IDO activity. It is suggested that this overall anti-inflammatory activity is mediated by a change in the relative production or activity of Th17 and regulatory T cell populations. Kynurenines may play an anti-inflammatory role also in CNS disorders such as Huntington's disease, Alzheimer's disease and multiple sclerosis, in which signs of inflammation and neurodegeneration are involved. The possibility is discussed that in Huntington's disease kynurenines interact with other anti-inflammatory molecules such as Human Lymphocyte Antigen-G which may be rn their susceptibility to arthritis and other inflammatory disorders. Copyright © 2020 Huang, Ogbechi, Clanchy, Williams and Stone.Dendritic cells (DCs) are specialized antigen presenting cells that instruct T cell responses through sensing environmental and inflammatory danger signals. Maintaining the homeostasis of the multiple functionally distinct conventional dendritic cells (cDC) subsets that exist in vivo is crucial for regulating immune responses, with changes in numbers sufficient to break immune tolerance. https://www.selleckchem.com/products/kn-62.html Using Ptpn22 -/- mice we demonstrate that the phosphatase PTPN22 is a highly selective, negative regulator of cDC2 homeostasis, preventing excessive population expansion from as early as 3 weeks of age. Mechanistically, PTPN22 mediates cDC2 homeostasis in a cell intrinsic manner by restricting cDC2 proliferation. A single nucleotide polymorphism, PTPN22R620W, is one of the strongest genetic risk factors for multiple autoantibody associated human autoimmune diseases. We demonstrate that cDC2 are also expanded in mice carrying the orthologous PTPN22619W mutation. As a consequence, cDC2 dependent CD4+ T cell proliferation and T follicular helper cell responses are increased. Collectively, our data demonstrate that PTPN22 controls cDC2 homeostasis, which in turn ensures appropriate cDC2-dependent T cell responses under antigenic challenge. Our findings provide a link between perturbations in DC development and susceptibility to a broad spectrum of PTPN22R620W associated human autoimmune diseases. Copyright © 2020 Purvis, Clarke, Montgomery, Colas, Bibby, Cornish, Dai, Dudziak, Rawlings, Zamoyska, Guermonprez and Cope.Epstein-Barr virus (EBV) is an oncogenic human herpes virus that was discovered in 1964. Viral non-coding RNAs, such as BamHI-A rightward fragment-derived microRNAs (BART miRNAs) or BamHI-H rightward fragment 1-derived miRNAs (BHRF1 miRNA) in EBV-infected cells have been recently reported. Host miRNAs are also upregulated upon EBV infection. Viral and host miRNAs are important in maintaining viral infection and evasion of host immunity. Although miRNAs in EBV-infected cells often promote cell proliferation by targeting apoptosis or cell cycle, this review focuses on the regulation of the recognition of the host immune system. This review firstly describes the location and organization of two clusters of viral miRNAs, then describes evasion from host immune surveillance systems by modulating viral gene expression or inhibiting innate and acquired immunity by viral miRNAs as well as host miRNAs. Another topic is the enigmatic depletion of viral miRNAs in several types of EBV-infected tumor cells. Finally, this review introduces the strong correlation of nasopharyngeal cancer cases with a newly identified single nucleotide polymorphism that enhances BART miRNA promoter activity. Copyright © 2020 Iizasa, Kim, Kartika, Kanehiro and Yoshiyama.Patients with triple-negative breast cancer (TNBC) suffer an unfavorable prognosis. Carboplatin (CBDCA) as a cytotoxic reagent has been widely administered to patients with cancer including TNBC. Programmed cell death protein 1 (PD-1) is an immune checkpoint, blockade of which unleashes T cell functions that kill cancer cells. However, the efficacy of CBDCA combined with anti-PD-1 antibodies in TNBC has not been determined. Patient-derived xenografts (PDX) were implanted to immune-deficient mice. Three mouse TNBC cell lines (4T1, EMT6, and E0771) were seeded to immune-competent mice. Tumor volumes and survival rates were monitored. CBDCA and anti-PD-1 antibodies were administered by intra-peritoneal injection at designated time points. Total CD8+ T cells, memory CD8+ T cells, and CD103+ dendritic cells (DC) in the tumor were measured by flow cytometry. Tumor-specific CD8+ T cells were quantified by the ELISpot assay. Administration of CBDCA to PDX-bearing mice induced increased levels of tumor cell necrosis and reduced tumor size. Treatment with CBDCA and anti-PD-1 antibodies reduced TNBC tumor volumes and slightly improved survival rates. More importantly, therapy with CBDCA and anti-PD-1 antibodies before surgery showed a remarkably improved, sustainable protection against a secondary tumor after surgery by a CD8+- T-cell-dependent manner, which required CCL4 expressed in the tumor and subsequently CD103+ DC recruited to the tumor microenvironment. Immunochemotherapy with CBDCA and anti-PD-1 antibodies before surgery improves the outcome of a secondary tumor after surgery via increasing the number of tumor-specific CD8+ T cells in the tumor microenvironment of murine TNBC. These results highlight the possibility to utilize this regimen in clinical practice. Copyright © 2020 Gao, Wang, Ji, Bai, Tian and Song.The tumor immune contexture plays a major role for the clinical outcome of patients. High densities of CD45RO+ T helper 1 cells and CD8+ T cells are associated with improved survival of patients with various cancer entities. In contrast, a higher frequency of tumor-infiltrating M2 macrophages is correlated with poor prognosis. Recent studies provide evidence that the tumor immune architecture also essentially contributes to the clinical efficacy of immune checkpoint inhibitor (CPI) therapy in patients. Pretreatment melanoma samples from patients who experienced a clinical response to anti-programmed cell death protein 1 (PD-1) treatment show higher densities of infiltrating CD8+ T cells compared to samples from patients that progressed during therapy. Anti-PD-1 therapy results in an increased density of tumor-infiltrating T lymphocytes in treatment responders. In addition, elevated frequencies of melanoma-infiltrating TCF7+CD8+ T cells are correlated with beneficial clinical outcome of anti-PD-1-treated patients.